Abstracts tagged "tobacco use and rheumatoid arthritis (RA)"

Abstract Number: 2298 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease Is Associated with Distinct Fine Specificities of Anti-Carbamylated Peptide/Protein Antibodies in Rheumatoid Arthritis
Raul Castellanos-Moreira¹, Sebastian Rodriguez-Garcia ², Virginia Ruiz-Esquide ³, Fernanda Hernández-González ⁴, Marcelo Sánchez ⁵, José Ramírez ⁶, Mariana Benegas ⁵, Carmen Lucena-Pozo ⁴, Carlos Agustí ⁴, Marc Boada ⁷, Odette Viñas ⁸, Estíbaliz Ruiz ⁸, Sergio Prieto-González ⁹, Jose Gomez-Puerta ¹, Jacobo Sellares ⁴, Juan Cañete ¹, Isabel Haro ¹⁰ and Raimon Sanmarti ¹, ¹Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ²Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, ³Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁴Department of Pneumology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁵Department of Radiodiagnosis, Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Department of Pathological Anatomy, Hospital Clínic, Barcelona, Barcelona, Spain, ⁷Department of Thoracic Surgery, Hospital Clínic, Barcelona, Barcelona, Spain, ⁸Department of Immunology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁹Department of Systemic Autoimmune Diseases Hospital Clínic, Barcelona, Barcelona, Spain, ¹⁰Unit of Synthesis and Biomedical Applications of Peptides, IQAC CSIC, Barcelona, Barcelona, Spain
Background/Purpose: Interstitial lung disease (ILD) is a common and severe complication of rheumatoid arthritis (RA). It has been associated with the presence of ACPA. Anti-carbamylated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].